A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

NCT02760797 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Emactuzumab
DRUG: RO7009789

Sponsor

Hoffmann-La Roche